Compare · ATEC vs BSX
ATEC vs BSX
Side-by-side comparison of Alphatec Holdings Inc. (ATEC) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATEC and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 58.7x ATEC ($1.23B).
- Over the past year, ATEC is down 32.9% and BSX is down 51.2% - ATEC leads by 18.3 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 1 for ATEC).
- BSX has more recent analyst coverage (25 ratings vs 17 for ATEC).
- Company
- Alphatec Holdings Inc.
- Boston Scientific Corporation
- Price
- $7.99-0.25%
- $48.79+0.47%
- Market cap
- $1.23B
- $72.16B
- 1M return
- +3.10%
- -13.75%
- 1Y return
- -32.91%
- -51.22%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 1
- 12
- Recent ratings
- 17
- 25
Alphatec Holdings Inc.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest ATEC
- SEC Form SD filed by Alphatec Holdings Inc.
- Director Valentine Keith bought $996,192 worth of shares (135,000 units at $7.38), increasing direct ownership by 139% to 232,271 units (SEC Form 4)
- SEC Form 10-Q filed by Alphatec Holdings Inc.
- Alphatec Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- ATEC Refinances Existing Debt with Inaugural Bank Facility
- ATEC Reports First Quarter Financial Results
- SEC Form DEFA14A filed by Alphatec Holdings Inc.
- SEC Form DEF 14A filed by Alphatec Holdings Inc.
- ATEC to Report First Quarter 2026 Financial Results on May 5, 2026
- SEC Form 4 filed by Marshall Tyson Eliot
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits